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Abstract: Dexfenfluramine is a variation of
fenfluramine which is used for weight reduction. The aim of the study is to determine
the hemodynamic and structural effects of
this drug on pulmonary circulation.
An experimintal study was carried out with
New Zealand Rabbits. A control group
(n=30) and an experimintal group (n=20)
was constituted. A four-week normal diet for
control group and dexfenfluramine plus normala diet for experimental group were applied. Body weights and pulmonary artery
pressures of groups were recorded and lungs
were collected for pathologic examination.
In experimintal group; Dexfenfluramine
raised systolic pulmonary artery pressures
significantly (p<0.01), whereas, there were
no meaningful changes on diastolic and mean

Introduction
Dexfenfluramine (lsomeride®) is a new drug in the
market that is still underinvestigation in many countries. Recently, it is largely used in our country for
weight reduction.
Dexfenfluramine is an fenfluramine derivative that
used as an appetite supressant. It is an antiobesity
drug. Dexfenfluramine is a dextro- rotalary (+) stereoisomer of fenfluramine that is a pure serotonin (5hydroxytryptamine; 5Ht) agonist devoid of dopaminergic or sympathominetic activity (1).
Dexfenfluramine is generally regarded by clinicians
as a safe medication. We tried to find out pulmonary
effect of it. Eary phases of therapy, mild and transitory side effects of the drug have been demonstrated
(2,3). Recent studies emphasize the risk of primary
pulmonary hypertension of appetite-supressant drugs
such as; derivatives of fenfluramine (fenfluramine and
dexfenfluramine), amphetamine-like anorexic agents

pulmonary artery pressures (p>0.05).
Weight reduction was obvious (f= 8.522,
p<0.01), in experimental group. There were
marked histopathologic changes in accordance with pulmonary hypertension. In
addition, squamouse metaplasia (n=1) and
tumorlet (n=3) formations were seen.
The use of dexfenfluramine was associated
with the development of primary pulmonary
hypertension. Duration and dosage relations
of the therapy and topical effects of the drug
should be investigated with further studies.
The reasons of tumorlet formation and squamouse metaplasia must be explained with
new researches.
Key Words: Dexfenfluramine, fenfluramine,
obesity, appetite depressants, pulmonary hypertension.

(diethylpropion [amfepramone], clobenzorex, fenproporex, mazindol and phenmetrazine) (4). In addition, rare cases of pulmonary hypertension and probability of neurotoxicity have been reported (5-7).
We sought the pulmonary paranchymal and vascular effects of dexfenfluramine.
Materials and Methods
Animals
An experimental study was carried out on New
Zealand Rabbits. Pulmonary artery pressures were obtained directly on living subjects with a cardiac ECGpressure monitor (Fig. 1). It was rather an invasive
procedure. Lack of post-operative cara units, animals
were sacrificed after measurements. A control group
(n=30) and an experimental group (n=20) were created. Body weights of groups were equal (p<0.01).
Body weights were between 2410 and 3150 g.
(Mean= 2753g.) (Table 1). All animals received care in
239
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compliance with the “Principles Of Laboratory Animal
Care” formulated by the National Society for Medical
Research.
Study Design
The animals were anaesthetized with Rompun“ (Xylazin Hydrochlorid) 15 mg/kg IM. and Ketalar‚ (Ketamine Hydrochlorid) 60 mg/kg IM. At the beginning,
tracheostomy was performed and a 12G cannula was
inserted into the trachea. Then sternotomy was performed and lungs were ventilated with a small ambulike device. After pericardiotomy, pulmonary artery
pressures were measured directy with a needle from
pulmonary infindibulum (Fig. 1).
Methods
The drug should be given orally because there are
no other pharmacological forms. Control group was
fed with normal diet, experimental group was fed
with dexfenfluramine added normal diet for four
weeks. Gastric content was seen then dexfenfluramine
(7.5mg/kg/day) was given once in a day via nasogastric way. Animals which were traumatized during
this application were excluded from the study. At the
beginning, during the 2nd and the 4th weeks of the
treatment, body weights were measured (Table 1). To
put aside the stress from nasogastric feeding, two
days later from the last measurement, pulmonary ar-

tery pressures were recorded. Lungs of 10 animal
from control group and all from the experimental
group were removed as previously mentioned.
Lung tissues were sampled one midline section
from both the right and left lungs. The tissues were
immersed in formalin (10%) fixative. An average biopsies were yielded (4 slices). Each slice was dehydrated and embedded in parafin. 5 micron-thick sections were stained with hematoxylin-eosin, and orcein
stain for elastic fibers.
The histologic sections were examined systematically changes in bood vessels and paranchyma were
recorded by two pathologists (RE-EB) who were unaware of the clinical findings. Preaciner and intraaciner
arteries were scored for severity of medial hypertrophy, intimal thickening and presence of focal paranchymal lesion. Morphometric analysis was not performed. Positive results were determined when the
changes seen more than 25%.
Based on the predominant histopathologic lesions,
the groups (control and experimental) were classified
into three groups (Table 2). Classification was done by
the two pathologists (RE-EB) without the knowledge
of hemodynamic parameters.
Data and Statistics
Pulmonary artery pressures were obtained as
Table 1.

Control Goup

Experimental

P

(n=30)

Group (n=13)

values

2753.33±32.3

2721.54±60.1

p>0.05

2823.33±33.1

2625.38±71.2

p>0.05

2906.67±34.4

2443.08±74.

p<0.01

Systolic

21.5±0.7

24.77±0.7

p<0.01

Diastolic

21.5±0.7

24.77±0.7

p>0.05

Mean

16.6±0.6

16.23±0.9

p>0.05

Body Weight
(gr).
At the beginning
(1st week)
Middle
(2nd week)
End
(4th week)
Pulmonary Artery
Pressures (mmHg)
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Body weights and pulmonary
artery pressures of groups.
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mmHg with a transducer (DELTRAN II, Utah Medical
Products, Inc. USA) and a recorder (cardiac ECGPressure monitor, SCHİLLER CH-6340 BAAR, Schiller
AG., Switzerland).
Body weights were determined as gram using a
bascul (BASTER TBT-5, BASTER Ltd., TURKIYE).
Lungs were examined with a light microscope (NIKON, HF X-II A, optiphot-2, Japar)
Results are presented as the mean and standard
error of the mean. Overall significance of differences
between groups was determined by a ANOVA test using Epi Info 5.0 pc program.
Results
7 animals in experimental group were excluded
from the study due to accidental respiratory insertion
(n=3), esophageal perforation (n=2) and hypoxic arrest (n=2) during nasogastric insertion. Body weights
were significantly reduced at the 4th week regarding
13 animals’ results. Mean body weights were
2721±60 g. and 2443± 74 g. (F=8.522, p<0.01) at
Figure 1.

the first week and fourth week respectively (Fig.2).
Systolic pressure of pulmonary artery was significantly elevated at the end of the study
(24.8±0.74mmHg, F=7.765, p=0.007). On the other
hand, the mean and diastolic pressure changes were
not significant. The difgerences between groups are illustrated on Figure 3.
Pulmonary vascular and paranchymal changes of
groups and statistical analysis of pathologic findings
were shown in Table 3. Taken into consideration of
all findings; 6 animals had G1, 1 animal had G2 and
6 animals had G3 pulmonary hypertension in experimental group, 1 had G1 and 1 had G3 pulmonary hypertension in control group (8-9). The most prominent vascular finding was arterial medial hypertrophy
(p<0.001) and the second one was venous muscularization (p<0.05). On the other hand there were no
meaningful (p>0.05) paranchymal changes (Table 3)
but squamose metaplasia (n=2) and tumorlet formation (n=3) were the most interesting paranchymal
findings of experimental group (Fig. 4.5).

Experimental desing.

02

P1

PIS26
PID 9
PIM17

P2
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Table 2.

Classification of histologic lesions for pulmonary hypertension

Group 1 (G1); Medial Hypertrophy
•

Medial lesions: Increased smooth muscle mass, reduplication of elastic lamina, may have fibrosis in
smooth muscle.

•

Intimal lesions: Minimal intimal proliferation.
GROUP 2 (G2); Arteriopathy with Plexiform Lesions

•

Medial lesions: Hypertrophied as in G1 above, may have fibrosis.

•

Intimal lesions: “Onion skin” proliferation of cellular elements, elastic fibers and matrix in conjunction
with “plexiform” lesions.
GROUP 3 (G3); Arteriopathy with Microthrombotic Lesions

•

Medial lesions: Hypertrophied as in G1 above, may have fibrosis.

•

Intimal lesions: Eccentric intimal cushions composed of cellular elements, connective tissue and matrix often in association with evidence of organized microthrombi; no plexiform lesions.

Discussion

Dexfenfluramine was recently taken the approval
from the Food and Drug Administration for the long
term treatment of obesity. There are very little experience of it’s usuage in long-term.

Since 1981, 25 cases Primary Pulmonary Hypertension (PPH) who were treated with fenfluramine,
have been reported (10-12). The mechanisms that are
responsible for pulmonary hypertension in patients using fenfluramine or other amphetamine-related appetite suppressants are unclear.

On histopathologic examination; findings of pulmonary hypertension were encountered in all animals
in the experimental group, regardless of their systolic
Figure 2.

3000 _
Control
Experimental

2900 _
2800 _

gr.

2700 _

2600 _

2500 _

2400 _

2nd-week
Duration of the therapy.
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_

_

2200 _

_

2300 _

2th-week

Body weight changes of groups. The
amount of weight loss was significant
(F=8.522,P<0.01).
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Figure 3.

24.7
25
Control

21.5

Experimental

20
17
15
mmHg.

12

The comparison of PAP values of
groups. Systolic pressure value
was higher in experimental group
(F=7.765, p<0.01)

.

16.2

11.4

10

5

0

Systolic

Diastolic
PAP

Mean

a. Repudlication of lamina elastica interna (LEI), and intimal proliferation.
(Orcein Stain, x175)

c .Medial hypertrophy (HE, x35)

b. Reduplication of LEI. (Orcein stain, x350)

d. Medial hypertrophy (HE,x175)
Figure 4.

Pulmonary vascular changes.
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5a.

Localize, alveolar epithelial hyperplasia (Tumorlet). (HE
stain, x35)
Figure

Squamose Metaplasia; bronchial epithelium. (HE stain,
x90.)

5. Pulmonary paranchymal changes.

pressures. Pulmonary hypertension was detected in
two animals in the control group.
In the experimental group; six animals, who had
G1, one had G2 and six had G3 pulmonary hypertension. Among these animals, who had G1 hypertension, five of them had paranchymal changes due to
abscess, pneumonia and fibrosis. Only one animal had
pulmonary hypertension without prominent paranchymal changes, so it can be accepted as drug effect. One animal had G2 pulmonary hypertension and
it was due to pneumonia. 6 animals had G3 hypertension. Three of them had additional paranchymal
findings, their vascular changes that causes hypertension were due to these paranchymal changes.
Whereas other three animals had vascular changes
without any promoting paranchymal findigs that produce pulmonary hypertension. Since, it can be explained by the effect of the drug.
In the control group; one animal had G1 and one
had G3 pulmonary hypertension. One of them had
pneumonia but other one had no paranchymal changes
that explains the hypertension.
As a result; no additional pulmonary paranchymal
changes have seen in one G1 and three G3 pulmonary
hypertension cases, so the seen vascular changes
thought to be the effect of the drug.
Except three animals there were no significant paranchymal changes between groups (p>0.05). These
three animals were in experimental group.
Marked alveolar epithelial hyperplasia (Tumorlet)
was identified in their sections, one of them had squa-
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5b.

mose metaplasia (Fig. 5). These changes can be produced by directly; aspiration of gastric content due to
regurgitation, or by indirectly; neoplastic effect of the
drug. Both tumorlet and squamose metaplasia might
be reversible. Nevertheless these kinds of lesions are
potentially risk for neoplasm.
In recent studies efforts focused on clinical trials
and their statistical significances rather than explanation of the pharmaco-pathologic mechanisms, since
there is a little experience on animal (rabbit) investigation of this drug (4,13).
The use of appetite supressants is a risk factor for
primary pulmonary hypertension, especially use lasting
more than three months (4). In our study, pulmonary
hypertension occured in one month. It is probably due
to the dosage (7.5 mg/kg/day). Duration and dosage
relation becomes important.
Weight loss was obvious (F= 8.522, p<0.01) in
the experimental group. It was the expecting effect of
the drug. The anorectic activity of these drugs depend
on the phenylethylamine molecule that takes place in
the structure. All of them have sympathomimetic and
serotoninergic effects in varying degrees (14). Cardiopulmonary effects of serotonin have been well demonstrated. Serotonin contracts isolated pulmonary arteries in dogs and humans it is a direct
vasoconstructor effect through potassium channel
blockade (4,15,16). In addition, it has a synergic effect on vascular smooth muscle cell proliferation with
platelet-derived growth factor (17). Moreover, patients
with PPH have higher levels of free plasma serotoin
than that of normal individuals (12).

F. CANDAN et al.

Vascular

Control Group

Experimental

Fischer

(n=10)

Group (n=13)
n
%

exact test

Changes
n
Arterial Medial

%

1

10

11

85

p=0.0006

p<0.001

1

10

6

46

p=0.09

p>0.05

Thrombosis

1

10

6

46

p=0.09

p>0.05

Arterial Elastic

0

0

3

23

p=0.23

p>0.05

Table 3:

Statistical analysis of groups
according to pulmonary
vascular and paranchymal
changes.

Hypertrophy
Arterial Intimal
Proliferation

Lamina Duplication
Venous

0

0

5

23

p=0.046

0

0

2 1

5

p=0.31

0

0

1

8

p=0.57

p<0.05

Muscularization
Wall

p>0.05

Thickening
Arterial plexiform

p>0.05

Lesions
Paranchymal

Control Group

Experimental

Fischer

(n=10)

Group (n=13)

exact test

Changes
n

%

n

%

Atelectasis

4

40

4

30

p=0.6

p>0.05

Emphysema

5

50

9

69

p=0.4

p>0.0

Pneumonia

2

20

7

54

p=0.19

p>0.05

Abscess

0

0

2

15

p=0.4

Congestion

4

40

8

61

p=0.41

p>0.05

Hemorrahge

3

30

7

54

p=0.40

p>0.05

Edema

1

10

2

15

p=0.6

Fibrosis

0

0

2

15

p=0.60

p>0.05

Pleuritis

1

10

3

23

p=0.60

p>0.05

Squamose
Metaplasia

0

0

2

15

p=0.49

p>0.05

Tumorlet

0

0

3

23

p=0.23

p>0.05

The present study shows that systolic pulmonary
arterial pressures are increased with dexfenfluramine
therapy (F= 7.765, p<0.01). We could not measure
plasma serotonin levels due to technical difficulties.
This elevation is probably due to increased level of serotonin and consequently vascular smooth muscle proliferation.

p>0.05

p>0.05

Obese persons are under at risk of various disease
including
primary
pulmonary
hypertension
(1:500.000). The risk is 30 times higher for obese
persons who use anorexic agents (4).
Most of obese patients prefer to use this kind of
drugs for esthetic perplexities. Body health is closely
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related with normal body mass. Obese patients should
prefer natural ways such as; changing eating habbit
and doing much more exercise.

We recommend clarifying hypertensive and neoplastic effects of this drug, before using it in long
term.
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